BridgeMD
Prevention study for Fragility Fracture
Official title PRevention of OsTEoporotiC FracTure 2 Pilot Study
ClinicalTrials.gov ID: NCT06134908
What this study is testing
- What it's testing
- With the aging of the world population, osteoporosis and fragility fractures have become global public health concerns. It has been estimated the population of people ≥60 years of age will increase from 229 million (16.2%) in 2017 to 479 million (35.1%) by 2050 in China.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Local residents (live in the city where the hospital is located for half a year or more);
- Hospitalized patients with fractures aged 50 years and above;
- First fracture, without history of fracture;
- Never diagnosed as "osteoporosis" before admission;
- No fracture history, and never receive any bone mineral density test, and never take anti-osteoporosis medication in the 4 years before admission;
You likely can't join if
- Patients with pathological fractures caused by tumor or infection;
- Patients with cognitive dysfunction or mental disorder;
- AIDS patients;
- Patients who refuse to follow-up, or have poor compliance for follow-up, or fail to understand and cooperate for follow-up;
- Hearing or visual impairment, and unable to communicate or read materials;
- Patients who have participate in other studies;
See the full eligibility criteria
- Local residents (live in the city where the hospital is located for half a year or more);
- Hospitalized patients with fractures aged 50 years and above;
- First fracture, without history of fracture;
- Never diagnosed as "osteoporosis" before admission;
- No fracture history, and never receive any bone mineral density test, and never take anti-osteoporosis medication in the 4 years before admission;
- Hospitalized patients with the following fractures: hip fracture, thoracic spine fracture, and lumbar spine fracture;
- New fragility fracture: fracture that occurs after minor trauma or daily activities, such as a fracture caused by a fall from standing height or less; fracture happened within 6 weeks;
- Not living in a nursing or rehabilitation institution before fracture;
- Possess reading ability, and can read and understand informed consent forms or medical materials independently.
- Patients with pathological fractures caused by tumor or infection;
- Patients with cognitive dysfunction or mental disorder;
- AIDS patients;
- Patients who refuse to follow-up, or have poor compliance for follow-up, or fail to understand and cooperate for follow-up;
- Hearing or visual impairment, and unable to communicate or read materials;
- Patients who have participate in other studies;
- Other conditions that the investigator considered inappropriate to enroll.
The study team makes the final eligibility decision.
Where it's taking place
- Changsha, China
- Dongguan, China
- Guangzhou, China
- Hangzhou, China
- Hefei, China
- Shenzhen, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changsha, China; Dongguan, China; Guangzhou, China; Hangzhou, China; Hefei, China; Shenzhen, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.